Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN016
MIFTS: 64

Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adenocarcinoma

About this section

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma 12 54 6 43 15 17 71
Adenocarcinomas 12 15

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:299
MeSH 43 D000230
NCIt 49 C2852
SNOMED-CT 67 35917007
UMLS 71 C0001418
Sources

Summaries for Adenocarcinoma

About this section
Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Adenocarcinoma, also known as adenocarcinomas, is related to small intestine adenocarcinoma and papillary adenocarcinoma. An important gene associated with Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Iron isomaltoside 1000 and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and colon, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Adenocarcinoma (/ˌædɪnoʊkɑːrsɪˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Sources

Related Diseases for Adenocarcinoma

About this section

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2354)
# Related Disease Score Top Affiliating Genes
1 small intestine adenocarcinoma 35.1 SMAD4 MLH1 KRAS CTNNB1
2 papillary adenocarcinoma 35.1 TP53 KRAS HRAS ERBB2 CDH1
3 mucinous adenocarcinoma 35.1 TP53 MLH1 KRAS ERBB2 EGFR CDKN2A
4 clear cell adenocarcinoma 35.0 TP53 SMAD4 PIK3CA
5 tubular adenocarcinoma 34.9 ERBB2 EGFR CTNNB1 CDH1
6 endometrial adenocarcinoma 34.9 TP53 MLH1 KRAS ERBB2 EGFR CTNNB1
7 signet ring cell adenocarcinoma 34.9 TP53 MLH1 KRAS HRAS ERBB2 CTNNB1
8 colon adenocarcinoma 34.9 TP53 SMAD4 PIK3CA MLH1 KRAS ERBB2
9 cervical adenocarcinoma 34.9 TP53 KRAS ERBB2 EGFR CDKN2A AKT1
10 wolffian duct adenocarcinoma 34.9 TP53 KRAS HRAS
11 bronchiolo-alveolar adenocarcinoma 34.9 KRAS EGFR CDH1
12 pancreatic adenocarcinoma 34.8 TP53 TGFBR2 SMAD4 PIK3CA MLH1 KRAS
13 scirrhous adenocarcinoma 34.8 ERBB2 CDH1
14 rectum adenocarcinoma 34.8 TP53 PIK3CA MLH1 KRAS HRAS ERBB2
15 mucinous lung adenocarcinoma 34.8 KRAS HRAS EGFR
16 ovary adenocarcinoma 34.8 TP53 SMAD4 PIK3CA MLH1 KRAS HRAS
17 colorectal adenocarcinoma 34.7 TP53 MLH1 KRAS HRAS ERBB4 ERBB2
18 gastric papillary adenocarcinoma 34.7 TP53 ERBB2
19 barrett's adenocarcinoma 34.7 TP53 KRAS ERBB2 CDKN2A
20 adenocarcinoma in situ 34.7 KRAS HRAS EGFR CDKN2A
21 gallbladder adenocarcinoma 34.7 TP53 PIK3CA ERBB2 EGFR
22 barrett esophagus 34.7 TP53 SMAD4 ERBB2 EGFR CTNNB1 CDKN2A
23 duodenum adenocarcinoma 34.6 MLH1 KRAS HRAS
24 endometrial serous adenocarcinoma 34.6 TP53 PIK3CA KRAS ERBB2
25 endocervical adenocarcinoma 34.6 TP53 PIK3CA ERBB2 CDKN2A
26 large intestine adenocarcinoma 34.6 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
27 bile duct adenocarcinoma 34.6 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
28 sebaceous adenocarcinoma 34.6 TP53 MLH1 ERBB2
29 apocrine adenocarcinoma 34.5 TP53 ERBB2 EGFR
30 vulvar adenocarcinoma 34.5 TP53 RB1
31 appendix adenocarcinoma 34.5 KRAS HRAS
32 nasal cavity adenocarcinoma 34.5 KRAS HRAS
33 urachal adenocarcinoma 34.5 KRAS BRAF
34 pulmonary adenocarcinoma in situ 34.4 KRAS HRAS EGFR
35 gastric diffuse adenocarcinoma 34.4 TP53 ERBB2 CDH1
36 rare adenocarcinoma of the breast 34.3 TP53 PIK3CA KRAS
37 pancreatic ductal adenocarcinoma 34.2 TP53 SMAD4 KRAS H19 ERBB2 EGFR
38 gastric adenocarcinoma 34.2 TP53 TGFBR2 SMAD4 PIK3CA MLH1 KRAS
39 suppression of tumorigenicity 12 34.1 TP53 TGFBR2 SMAD4 PIK3CA KRAS HRAS
40 adenosquamous carcinoma 34.1 TP53 SMAD4 PIK3CA KRAS EGFR
41 esophagus adenocarcinoma 34.1 TP53 HNF1A-AS1 ERBB2 EGFR CTNNB1 CDKN2A
42 breast adenocarcinoma 33.9 TP53 RB1 PIK3CA KRAS H19 ERBB2
43 adenoma 33.7 TP53 TGFBR2 SMAD4 PIK3CA MLH1 KRAS
44 adenoid cystic carcinoma 33.7 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
45 serous cystadenocarcinoma 33.7 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
46 thyroid gland follicular carcinoma 33.6 TP53 HRAS AKT1
47 renal cell carcinoma, papillary, 1 33.6 TP53 PIK3CA HRAS FGFR3 ERBB2 EGFR
48 merkel cell carcinoma 33.6 TP53 RB1 CTNNB1 CDKN2A AKT1
49 cystadenocarcinoma 33.5 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
50 colorectal adenoma 33.5 TP53 MLH1 KRAS HRAS EGFR CTNNB1

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma
Sources

Symptoms & Phenotypes for Adenocarcinoma

About this section

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 72)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.2 HRAS KRAS PIK3CA BRAF EGFR
2 Decreased viability GR00055-A-2 11.2 HRAS KRAS PIK3CA BRAF EGFR
3 Decreased viability GR00055-A-3 11.2 KRAS
4 Decreased viability GR00106-A-0 11.2 KRAS
5 Decreased viability GR00107-A-1 11.2 TGFBR2
6 Decreased viability GR00221-A-1 11.2 AKT1 FGFR3 HRAS KRAS PIK3CA CDH1
7 Decreased viability GR00221-A-2 11.2 AKT1 FGFR3 HRAS KRAS PIK3CA
8 Decreased viability GR00221-A-3 11.2 AKT1 FGFR3 HRAS CDKN2A ERBB2 TGFBR2
9 Decreased viability GR00221-A-4 11.2 AKT1 PIK3CA BRAF CDKN2A ERBB2 TGFBR2
10 Decreased viability GR00249-S 11.2 AKT1 FGFR3 BRAF TGFBR2
11 Decreased viability GR00301-A 11.2 KRAS BRAF CDH1 ERBB4
12 Decreased viability GR00342-S-1 11.2 ERBB4
13 Decreased viability GR00381-A-1 11.2 KRAS BRAF
14 Decreased viability GR00402-S-2 11.2 PIK3CA CDH1 TGFBR2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.5 TGFBR2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.5 PIK3CA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.5 TGFBR2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 10.5 TGFBR2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.5 TGFBR2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.5 ERBB2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.5 TGFBR2
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.5 TGFBR2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.5 PIK3CA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.5 AKT1 PIK3CA
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.5 ERBB2
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 10.5 TGFBR2
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.5 PIK3CA
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.5 AKT1 PIK3CA
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.5 PIK3CA
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 10.5 TGFBR2
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 10.5 TGFBR2
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.5 PIK3CA
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.5 AKT1 PIK3CA
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.5 PIK3CA
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.5 AKT1
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.5 PIK3CA
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.5 TGFBR2
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.5 TGFBR2
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.5 AKT1
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 10.5 TGFBR2
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.5 TGFBR2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.2 MLH1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.2 SMAD4
44 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.2 SMAD4
45 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.2 KRAS
46 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.2 MLH1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.2 APC
48 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.2 BRAF
49 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.2 RB1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.2 RB1

MGI Mouse Phenotypes related to Adenocarcinoma:

45 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
2 behavior/neurological MP:0005386 10.54 AKT1 APC BRAF CDKN2A CTNNB1 ERBB2
3 cardiovascular system MP:0005385 10.53 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
4 endocrine/exocrine gland MP:0005379 10.53 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
5 homeostasis/metabolism MP:0005376 10.5 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
6 integument MP:0010771 10.5 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
7 digestive/alimentary MP:0005381 10.49 APC BRAF CDH1 CDKN2A CTNNB1 EGFR
8 growth/size/body region MP:0005378 10.49 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
9 embryo MP:0005380 10.48 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
10 immune system MP:0005387 10.46 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
11 mortality/aging MP:0010768 10.46 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
12 craniofacial MP:0005382 10.43 APC BRAF CTNNB1 EGFR ERBB2 ERBB4
13 hematopoietic system MP:0005397 10.42 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
14 neoplasm MP:0002006 10.41 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
15 nervous system MP:0003631 10.36 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
16 muscle MP:0005369 10.34 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
17 normal MP:0002873 10.28 AKT1 APC BRAF CDH1 CTNNB1 EGFR
18 liver/biliary system MP:0005370 10.26 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
19 adipose tissue MP:0005375 10.24 AKT1 APC BRAF EGFR PIK3CA RB1
20 limbs/digits/tail MP:0005371 10.24 APC BRAF CTNNB1 EGFR ERBB2 FGFR3
21 hearing/vestibular/ear MP:0005377 10.19 APC BRAF CTNNB1 EGFR FGFR3 KRAS
22 reproductive system MP:0005389 10.16 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
23 no phenotypic analysis MP:0003012 10.13 CDH1 CDKN2A CTNNB1 EGFR FGFR3 HRAS
24 renal/urinary system MP:0005367 10.06 APC BRAF CTNNB1 EGFR FGFR3 HRAS
25 pigmentation MP:0001186 10.02 APC BRAF CDKN2A CTNNB1 EGFR KRAS
26 respiratory system MP:0005388 10 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
27 skeleton MP:0005390 9.83 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
28 vision/eye MP:0005391 9.4 APC BRAF CDKN2A CTNNB1 EGFR FGFR3
Sources

Drugs & Therapeutics for Adenocarcinoma

About this section

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 810)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Desflurane Approved Phase 4 57041-67-5 42113
4
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
5
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
6
Prilocaine Approved Phase 4 721-50-6 4906
7
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
8
Clarithromycin Approved Phase 4 81103-11-9 84029
9
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
10
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
11
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
12
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
13
Ofloxacin Approved Phase 4 82419-36-1 4583
14
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
15
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
16
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
17
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
18
Zinc Approved, Investigational Phase 4 7440-66-6 32051
19
Tranexamic Acid Approved Phase 4 1197-18-8 5526
20
Sodium citrate Approved, Investigational Phase 4 68-04-2
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
26
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
27
tannic acid Approved Phase 4 1401-55-4
28
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
29
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
30
Polaprezinc Experimental Phase 4 107667-60-7
31
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
32 Endostar protein Phase 4
33 Endostatins Phase 4 71581480
34 Hypolipidemic Agents Phase 4
35 Anticholesteremic Agents Phase 4
36 Lipid Regulating Agents Phase 4
37 Monophosphoryl lipid A Phase 4
38 Respiratory System Agents Phase 4
39 Expectorants Phase 4
40 Anesthetics, Inhalation Phase 4
41 Antacids Phase 4
42 Anti-Ulcer Agents Phase 4
43 Excitatory Amino Acid Antagonists Phase 4
44 Anesthetics, Dissociative Phase 4
45 Muscarinic Antagonists Phase 4
46 Cholinergic Antagonists Phase 4
47 Cytochrome P-450 CYP3A Inhibitors Phase 4
48 Proton Pump Inhibitors Phase 4
49 Hepcidins Phase 4
50 Antitubercular Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 4864)
# Name Status NCT ID Phase Drugs
1 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
2 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
3 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
4 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
5 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
6 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
7 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
8 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
9 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
10 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
11 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
12 Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
13 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
14 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
15 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
16 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
17 Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
18 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
19 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
20 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
21 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
22 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
23 Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy Completed NCT03164590 Phase 4 Ketamine;dexmedetomidine;bupivacaine
24 Clinical Outcomes of Endoscopic Resection for Treating Extremely Well Differentiated Intestinal-type Adenocarcinoma (WHYX Lesion) Completed NCT01451034 Phase 4
25 Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients Completed NCT01180452 Phase 4
26 A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy ) Completed NCT01661166 Phase 4 Fesoterodine;Placebo oral tablet
27 An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
28 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
29 Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer Completed NCT01579721 Phase 4
30 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
31 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
32 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
33 A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
34 Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET Completed NCT00904410 Phase 4
35 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
36 An Open Label Study to Determine the Efficacy of Ferric Carboxymaltose in Preoperative Colorectal Cancer Related Anaemia, and to Develop Biomarkers to Predict Response to This Treatment Strategy Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
37 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
38 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
39 An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer Completed NCT00198276 Phase 4
40 Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases Completed NCT01972490 Phase 4 avastin;mFOLFOX6
41 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
42 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
43 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
44 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
45 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
46 Sequential Helicobacter Pylori Eradication Therapy in Myanmar; a Randomized Clinical Trial of Efficacy and Tolerability Completed NCT04132479 Phase 4 Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg;Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg
47 Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
48 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
49 An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE) Recruiting NCT04078152 Phase 4 Durvalumab
50 Can the Prophylactic Administration of Tranexamic Acid Reduce Blood Loss After Robotic-assisted Radical Prostatectomy? The RARPEX (Robotic Assisted Radical Prostatectomy With TranEXamic Acid) Study. Recruiting NCT04319614 Phase 4 Tranexamic Acid Injectable Product;Placebos

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thiotepa

Cochrane evidence based reviews: adenocarcinoma

Sources

Genetic Tests for Adenocarcinoma

About this section
Sources

Anatomical Context for Adenocarcinoma

About this section

MalaCards organs/tissues related to Adenocarcinoma:

40
Lung, Prostate, Colon, Pancreas, Breast, Cervix, Lymph Node
Sources

Publications for Adenocarcinoma

About this section

Articles related to Adenocarcinoma:

(show top 50) (show all 56410)
# Title Authors PMID Year
1
Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. 54 61
19892429 2010
2
Role of CDK8 and beta-catenin in colorectal adenocarcinoma. 54 61
20514474 2010
3
The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. 61 54
20339853 2010
4
Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. 61 54
19949912 2010
5
A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis. 54 61
20197492 2010
6
Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. 61 54
19415536 2010
7
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. 61 54
20031160 2010
8
Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. 61 54
20518902 2010
9
Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. 54 61
20213678 2010
10
Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? 54 61
20182859 2010
11
MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain. 61 54
20090516 2010
12
DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. 61 54
20372780 2010
13
Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. 54 61
20038908 2010
14
Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions. 61 54
20518411 2010
15
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. 54 61
20439191 2010
16
Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. 61 54
20372850 2010
17
A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. 61 54
20173733 2010
18
Identification of gastrointestinal contamination in endoscopic ultrasound-guided pancreatic fine needle aspiration. 54 61
20518405 2010
19
True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. 61 54
20407331 2010
20
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. 61 54
19856421 2010
21
Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns. 61 54
20216381 2010
22
Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. 61 54
19280218 2010
23
Diagnostic value and implications of vimentin expression in normal, reactive and neoplastic endocervical epithelium. 61 54
20350213 2010
24
Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). 54 61
20350215 2010
25
Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. 61 54
20062011 2010
26
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. 61 54
20146302 2010
27
Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor. 54 61
20004952 2010
28
Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. 61 54
20377670 2010
29
Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. 61 54
20040392 2010
30
Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. 54 61
20107918 2010
31
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 54 61
20154720 2010
32
Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. 61 54
20074157 2010
33
Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. 61 54
20108111 2010
34
Integration of biomarkers including molecular targeted therapies in head and neck cancer. 61 54
20237991 2010
35
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. 54 61
20233436 2010
36
Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas. 54 61
19609729 2010
37
Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. 54 61
19875957 2010
38
Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas. 54 61
20515563 2010
39
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. 61 54
19926591 2010
40
Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. 54 61
20158339 2010
41
SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. 54 61
20393008 2010
42
Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. 61 54
20183914 2010
43
Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. 54 61
20193080 2010
44
Significance of mucin expression in pancreatobiliary neoplasms. 61 54
19787286 2010
45
Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. 54 61
20398190 2010
46
PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. 61 54
20061933 2010
47
Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman. 54 61
19926523 2010
48
Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. 54 61
19843025 2010
49
KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. 54 61
19813061 2010
50
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. 54 61
20103678 2010
Sources

Variations for Adenocarcinoma

About this section

ClinVar genetic disease variations for Adenocarcinoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230

Copy number variations for Adenocarcinoma from CNVD:

7 (show all 49)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25149 1 184907591 184916179 Amplification PTGS2 Adenocarcinoma
2 33704 1 47467454 47552406 Amplification STIL Adenocarcinoma
3 66093 12 25249446 25295130 Amplification KRAS Adenocarcinoma
4 66576 12 3100000 5300000 Gain LOC399986 Adenocarcinoma
5 66578 12 3100000 5300000 Gain LOC441627 Adenocarcinoma
6 66580 12 3100000 5300000 Gain TSPAN9 Adenocarcinoma
7 74649 13 109973413 110012072 Amplification RAB20 Adenocarcinoma
8 87573 14 74815283 74818665 Amplification FOS Adenocarcinoma
9 93655 15 57100000 61500000 Loss RORA Adenocarcinoma
10 95696 15 79500000 83000000 Loss DNM1DN11-6 Adenocarcinoma
11 95698 15 79500000 83000000 Loss LOC159170 Adenocarcinoma
12 95700 15 79500000 83000000 Loss LOC161527 Adenocarcinoma
13 95702 15 79500000 83000000 Loss LOC388152 Adenocarcinoma
14 95704 15 79500000 83000000 Loss LOC388160 Adenocarcinoma
15 95706 15 79500000 83000000 Loss LOC440300 Adenocarcinoma
16 95708 15 79500000 83000000 Loss LOC440301 Adenocarcinoma
17 97921 16 14700000 16700000 Loss Adenocarcinoma
18 107538 17 15900000 22100000 Loss Adenocarcinoma
19 111139 17 35097918 35138441 Amplification ERBB2 Adenocarcinoma
20 123836 18 89115825 89123587 Amplification SPP1 Adenocarcinoma
21 135625 2 118600000 122100000 Gain Adenocarcinoma
22 171545 3 169200000 172500000 Gain EVI1 Adenocarcinoma
23 171548 3 169200000 172500000 Gain LOC389174 Adenocarcinoma
24 171550 3 169200000 172500000 Gain MDS1 Adenocarcinoma
25 172147 3 177300000 180600000 Gain KCNMB3 Adenocarcinoma
26 172149 3 177300000 180600000 Gain PIK3CA Adenocarcinoma
27 172225 3 178866310 178952497 Gain PIK3CA Adenocarcinoma
28 172903 3 187500000 189400000 Gain MASP1 Adenocarcinoma
29 173068 3 189400000 193800000 Gain FGF12 Adenocarcinoma
30 173072 3 189400000 193800000 Gain TP73L Adenocarcinoma
31 173431 3 193800000 199501827 Gain KIAA0226 Adenocarcinoma
32 173434 3 193800000 199501827 Gain LOC220729 Adenocarcinoma
33 173436 3 193800000 199501827 Gain LOC440996 Adenocarcinoma
34 173438 3 193800000 199501827 Gain LOC440997 Adenocarcinoma
35 173440 3 193800000 199501827 Gain LOC440998 Adenocarcinoma
36 173442 3 193800000 199501827 Gain OPA1 Adenocarcinoma
37 206066 6 135544145 135582003 Amplification MYB Adenocarcinoma
38 218057 7 107200000 137300000 Amplification Adenocarcinoma
39 218695 7 116312458 116438439 Copy number MET Adenocarcinoma
40 225387 7 45400000 54000000 Copy number EGFR Adenocarcinoma
41 226106 7 55054218 55242525 Amplification EGFR Adenocarcinoma
42 230093 7 97900000 104400000 Gain TRRAP Adenocarcinoma
43 230096 7 97900000 104400000 Gain ZKSCAN1 Adenocarcinoma
44 230097 7 97900000 104400000 Gain ZNF3 Adenocarcinoma
45 230098 7 97900000 104400000 Gain ZNF38 Adenocarcinoma
46 233908 8 128816946 128822855 Amplification MYC Adenocarcinoma
47 239383 8 38973661 39081936 Amplification ADAM9 Adenocarcinoma
48 240761 8 55041668 55097561 Translate TCEA1 Adenocarcinoma
49 241225 8 59800000 146274826 Copy number Adenocarcinoma
Sources

Expression for Adenocarcinoma

About this section
Search GEO for disease gene expression data for Adenocarcinoma.
Sources

Pathways for Adenocarcinoma

About this section

Pathways related to Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.34 TP53 TGFBR2 SMAD4 PIK3CA KRAS HRAS
2
Innate Immune System 65
Show member pathways
 14.18 TP53 PIK3CA KRAS HRAS FGFR3 ERBB4
3
ERK Signaling 63
Show member pathways
 14 TP53 TGFBR2 SMAD4 RB1 KRAS HRAS
4
HIV Life Cycle 65
Show member pathways
 13.9 TGFBR2 SMAD4 PIK3CA KRAS HRAS FGFR3
5
GPCR Pathway 63
Show member pathways
 13.89 TP53 TGFBR2 SMAD4 RB1 KRAS HRAS
6
PEDF Induced Signaling 63
Show member pathways
 13.86 TP53 TGFBR2 SMAD4 KRAS HRAS FGFR3
7
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.75 TGFBR2 SMAD4 KRAS HRAS FGFR3 ERBB4
8
TGF-Beta Pathway 63
Show member pathways
 13.74 TP53 TGFBR2 SMAD4 PIK3CA KRAS HRAS
9
Developmental Biology 65
Show member pathways
 13.69 SMAD4 PIK3CA KRAS HRAS FGFR3 ERBB4
10
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.64 TP53 PIK3CA KRAS HRAS FGFR3 ERBB4
11
Integrin Pathway 63
Show member pathways
 13.56 TGFBR2 PIK3CA KRAS HRAS EGFR CTNNB1
12
Akt Signaling 63
Show member pathways
 13.56 TP53 KRAS HRAS FGFR3 ERBB4 ERBB2
13
Cytokine Signaling in Immune system 65
Show member pathways
 13.56 TP53 PIK3CA KRAS HRAS FGFR3 ERBB4
14
PAK Pathway 63
Show member pathways
 13.5 TGFBR2 SMAD4 KRAS HRAS FGFR3 ERBB2
15
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.48 KRAS HRAS FGFR3 ERBB4 ERBB2 EGFR
16
CREB Pathway 63
Show member pathways
 13.46 KRAS HRAS FGFR3 ERBB4 ERBB2 EGFR
17
IL-2 Pathway 63
Show member pathways
 13.39 TP53 KRAS HRAS ERBB4 ERBB2 EGFR
18
Parkinson disease 36
Show member pathways
 13.35 TP53 PIK3CA KRAS HRAS CTNNB1 BRAF
19
GAB1 signalosome 65
Show member pathways
 13.28 TP53 PIK3CA FGFR3 ERBB4 ERBB2 EGFR
20
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.28 TP53 TGFBR2 SMAD4 RB1 PIK3CA KRAS
21
TNFR1 Pathway 63
Show member pathways
 13.26 TP53 RB1 PIK3CA KRAS HRAS EGFR
22
Phospholipase-C Pathway 63
Show member pathways
 13.24 TP53 KRAS HRAS FGFR3 EGFR BRAF
23
G-Beta Gamma Signaling 63
Show member pathways
 13.21 KRAS HRAS EGFR CTNNB1 CDKN2A BRAF
24
PI3K-Akt signaling pathway 36
Show member pathways
 13.19 TP53 RB1 PIK3CA KRAS HRAS FGFR3
25
fMLP Pathway 63
Show member pathways
 13.18 TP53 KRAS HRAS CTNNB1 CDH1 BRAF
26
Human cytomegalovirus infection 36
Show member pathways
 13.16 TP53 RB1 PIK3CA KRAS HRAS EGFR
27
Focal Adhesion 36 1
Show member pathways
 13.13 RB1 PIK3CA KRAS HRAS ERBB2 EGFR
28
Sertoli-Sertoli Cell Junction Dynamics 63
Show member pathways
 13.12 TGFBR2 KRAS HRAS CTNNB1 CDH1 BRAF
29
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.12 TGFBR2 PIK3CA KRAS HRAS ERBB2 EGFR
30
Aldosterone synthesis and secretion 36
Show member pathways
 13.12 RB1 KRAS HRAS EGFR CTNNB1 CDKN2A
31
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.1 TGFBR2 PIK3CA KRAS HRAS FGFR3 ERBB4
32
Development Angiotensin activation of ERK 22
Show member pathways
 13.03 PIK3CA KRAS HRAS EGFR BRAF AKT1
33
MAPK signaling pathway 36 1
13.01 TP53 TGFBR2 KRAS HRAS FGFR3 ERBB4
34
Ras signaling pathway 36
Show member pathways
 12.97 PIK3CA KRAS HRAS FGFR3 EGFR CTNNB1
35
Development HGF signaling pathway 22
Show member pathways
 12.97 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
36
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.96 TP53 PIK3CA KRAS HRAS FGFR3 ERBB4
37
Beta-Adrenergic Signaling 63
Show member pathways
 12.93 KRAS HRAS CTNNB1 BRAF AKT1
38
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.91 PIK3CA KRAS HRAS BRAF AKT1
39
Glioma 36
Show member pathways
 12.9 TP53 RB1 PIK3CA KRAS HRAS ERBB2
40
Apoptotic execution phase 65
Show member pathways
 12.89 TP53 CTNNB1 CDH1 APC AKT1
41
Apoptosis Modulation and Signaling 1
Show member pathways
 12.89 TP53 PIK3CA KRAS HRAS CDKN2A AKT1
42
4-1BB Pathway 63
Show member pathways
 12.88 TP53 RB1 KRAS HRAS EGFR BRAF
43
ErbB signaling pathway 36 1
Show member pathways
 12.87 TP53 PIK3CA KRAS HRAS FGFR3 ERBB4
44
Relaxin signaling pathway 36
Show member pathways
 12.86 TGFBR2 PIK3CA KRAS HRAS EGFR AKT1
45
Regulation of actin cytoskeleton 36 1
12.86 PIK3CA KRAS HRAS FGFR3 EGFR BRAF
46
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.84 PIK3CA KRAS HRAS